ClinicalTrials.gg
Not yet recruitingNCT07864467BHF-COLLATEUpdated Oct 7, 2026

BHF-COLLATE: UK Prospective, Multi-centre, Observational, Cardio-oncology Anthracycline Registry

An observational study in Cancer and / or Hematological Malignancy and Anthracycline-induced Cardiotoxicity, sponsored by South Tees Hospitals NHS Foundation Trust. Not yet recruiting at 6 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Primary conditionHematologic NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hematologic Neoplasms
Why
  1. The study's listed conditions name Hematologic Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by South Tees Hospitals NHS Foundation Trust · Observational

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Hematologic Neoplasms with a site in United Kingdom — 24 open to participants now, 30 under way, 11 of them phase 3. Hematologic Neoplasms · United Kingdom.

Started
2026
with 6 others
Observational
9 of 72
4 open now
Primary completion
2029-11
later than 21 of 29 live
Registered
71st of 72
by date

Among the 72 studies in Hematologic Neoplasms with a site in United Kingdom, this one is one of 7 that started in 2026, is one of 9 observational ones, reaches primary completion later than 21 of the 29 other live ones, and was the 71st registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

24 of the 72 studies in Hematologic Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Hematologic Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

The study aims to collect information on how cancer treatment affects heart health. This will include collecting baseline medical information, storing blood samples, recording cancer treatment, and analysing heart scans across about 200 patients in several UK hospitals. We are aiming to: collect health information and store blood samples, alongside heart scans, to learn more about heart health after chemotherapy; improve understanding of why some patients develop heart problems, so that better tests, monitoring, and treatments can be developed in the future; build a UK-wide research group.

Read the detailed description

The overarching rationale of BHF-COLLATE is to establish the first phase of a UK multicentre cardio-oncology registry platform focused on anthracycline chemotherapy. Phase I is primarily designed as a feasibility and infrastructure building registry to establish a functioning multidisciplinary research network, harmonised study procedures, core imaging and biobanking workflows, and scalable data collection processes capable of supporting future national registry expansion and interventional clinical trials.

In parallel, exploratory clinical, imaging and biomarker analyses will improve understanding of the cardiovascular consequences of anthracycline chemotherapy in real-world clinical practice and help inform the design of future translational and interventional cardio-oncology studies.

Through the establishment of this first phase, and recruitment of a multicentre UK anthracycline registry, the study aims to comprehensively phenotype patients receiving anthracycline chemotherapy in order to:

establish a collaborative research network and platform to support future interventional clinical trials in cardio-oncology facilitate translational research through the biobanking of clinical samples linked to detailed baseline clinical assessments, cardiac imaging, and longitudinal follow-up data generate mechanistic insights to inform the design of future clinical trials and the development of improved diagnostic, risk-stratification, and surveillance strategies.

03

Conditions studied

  • Cancer and / or Hematological Malignancy
  • Anthracycline-induced Cardiotoxicity

Browse trials for

04

In context

Hematologic Neoplasms Reclassified

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

This study's planned enrollment of 200 is close to the median of 191 across 324 observational studies indexed under Hematologic Neoplasms.

Browse Hematologic Neoplasms studies →

Lead sponsor

South Tees Hospitals NHS Foundation Trust is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Compared within Hematologic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be recruited from centres treating haemato-oncology and oncology patients and will be adult patients (18 years and above) who are due to receive anthracycline-based chemotherapy for their cancer* and provide written informed consent prior to study participation.

*Participants are likely to be those being treated for breast cancer, lymphoma and sarcoma. Where patients need an expedited start to their anthracycline-based chemotherapy regimen for urgent clinical reasons that precludes enrolment prior to the start of cycle 1 (e.g. patients with NHL where treatment must start within a couple of days), they can still be included as long as consent, baseline assessments and eligibility is confirmed prior to the start of cycle 2.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with confirmed solid organ or haematological ;
  • Adults aged 18 years or older;
  • Planned to receive anthracycline chemotherapy; or prior to the start of the second cycle of anthracycline chemotherapy for those who required an urgent start to their chemotherapy for clinical reasons;
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • Expected lifespan of under one year;
  • Not expected to complete the planned course of chemotherapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Anthracycline patients

    Adult patients with confirmed solid organ or haematological malignancy; Adults aged 18 years or older; Planned to receive anthracycline chemotherapy; or prior to the start of the second cycle of anthracycline chemotherapy for those who required an urgent start to their chemotherapy for clinical reasons.

07

What researchers measure

Primary outcomes

  1. Number of participants recruited

    Recruitment of 200 participants with ≥75% of patients at medium or higher HFA-ICOS score

    Time frame: 16 months

Secondary outcomes

  1. Cardiac function

    Cardiac function assessed by core lab artificial intelligence (AI) enabled echocardiogram via measurement of left ventricular ejection fraction (LVEF) in (%).

    Time frame: 12 months

  2. Cardiac function

    Cardiac function assessed by core lab artificial intelligence (AI) enabled echocardiogram via measurement of global longitudinal strain (GLS) in a negative percentage (%).

    Time frame: 12 months

  3. Cancer outcomes

    Cancer outcomes - Entries recorded in the patient's medical records including cancer relapse/recurrence and diagnosis.

    Time frame: 12 months

  4. Cancer outcomes

    Cancer treatment completeness including number of cycles whether dosage was changed/delayed/reduced/discontinued - total dose of anthracycline received in (mg/m²) of body surface area.

    Time frame: 12 months

  5. Cardiovascular Outcomes

    1Cardiovascular outcomes including cancer therapy related cardiac dysfunction (CTRCD). Entries as recorded in the patients' medical records including: * new diagnoses of heart failure * new diagnoses of atrial fibrillation * new diagnoses of myocardial infarction * new diagnoses of stroke or Transient Ischaemic Attack (TIA) * new diagnoses of deep vein thrombosis (DVT) * new diagnoses of Pulmonary Embolous (PE).

    Time frame: 12 months

  6. Quality of Life

    Measurement of health-related quality of life of cancer patients through completion of EORTC-QLQ-C30 questionnaire. Most items use a 4-point scale ranging from 1 ("Not at all") to 4 ("Very much"); the global health/QoL items towards the end of the questionnaire use a 7-point scale from 1 ("Very poor") to 7 ("Excellent"). Overall scores are calculated by adding up the numerical response values in a section and calculating an average score. This score is then converted to a 0-100 score using the scoring manual. A higher score means a better level of functioning or higher quality of life, a lower score signifies lower QoL.

    Time frame: 12 months

  7. Quality of Life

    Measurement of patient-reported Quality of Life assessments through completion of the EQ-5D-5L questionnaire.

    Time frame: 12 months

  8. Biobanking and data collection

    To facilitate translational research through the biobanking of clinical samples (including biomarkers and genomics)

    Time frame: 12 months

08

Study locations

6 sites
09

References and documents

Individual participant data

Plan to share: Yes — We are committed to sharing samples and de-identified individual level data, where a rigorous research question may be answered. Appropriate data and material sharing agreements and Data Protection Impact Assesments (DPIA)s will be put in place where required. The research team including the Chief Investigator and Sponsor will consider proposals from researchers as long as there is no constraint due to: Ethical approval and informed consent The request does not require the data/samples prior to publication of key findings or appropriate agreements are able to be place to protect the original work. The request for data and/or samples does not extend beyond that which is needed to answer the specific research question. Overall responsibility for data collection lies with the Chief Investigator. Study data will be handled, computerised and stored in accordance with the Data Protection Act 2018, and local policy.

Supporting information: Study protocol, Clinical study report

Time frame: After primary and secondary analyses have occured

Access criteria: The research team including the Chief Investigator and Sponsor will consider proposals from researchers as long as there are no constraints as described earlier.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Nov 2029, 38 months later.

Of 164 non-industry observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's planned 38 months is below that.

Counting every sponsor, half of 186 studies reached it within 74 months; a quarter within 34 and three quarters within 322.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2026
First posted
Oct 7, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Nov 30, 2029
CompletionEst.
Nov 30, 2029
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07864467
Lead sponsor
South Tees Hospitals NHS Foundation Trust
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Nov 30, 2029 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Oct 7, 2026

Study contacts

BHF COLLATE study team
Contact
stees.bhfcollate@nhs.net
01642 850 850 ext. 58441
David Austin
principal investigator · South Tees Hospitals NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion